The observed potency could be related to a target other than EGFR, as the corresponding 7-iodo 32 has similar EGFR activity to 28, but was not potent in the patient-derived chordoma lines or the WS1 control (IC50 = > 100 μM). Here, EGFR is linked to chordoma.